<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430778</article-id><article-id pub-id-type="pmcid-ver">PMC12430778.1</article-id><article-id pub-id-type="pmcaid">12430778</article-id><article-id pub-id-type="pmcaiid">12430778</article-id><article-id pub-id-type="pmid">40557546</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002673</article-id><article-id pub-id-type="publisher-id">IJS-D-25-01307</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Systematic review and/or Meta-analysis</subject></subj-group></article-categories><title-group><article-title>Comparison of total thyroidectomy and lobectomy for intermediate-risk papillary thyroid carcinoma with lateral lymph node metastasis: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xinhua</given-names></name><degrees>MM</degrees><email>lixinhua0520@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gui</surname><given-names initials="Z">Zhiqiang</given-names></name><degrees>MD</degrees><email>guizhiqiang6332@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="C">Chun</given-names></name><degrees>MM</degrees><email>xuchunztt@126.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiang</surname><given-names initials="J">Jingzhe</given-names></name><degrees>MD</degrees><email>1916851431@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ming</surname><given-names initials="J">Jie</given-names></name><degrees>MD, PhD</degrees><email>mingjiewh@126.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="T">Tao</given-names></name><degrees>MD, PhD</degrees><email>huangtaowh@163.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="M">Mingming</given-names></name><degrees>MM</degrees><email>jmm2009001@163.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="H">Hao</given-names></name><degrees>MD, PhD</degrees><email>haozhang@cmu.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhihong</given-names></name><degrees>MD, PhD</degrees><email>wangzhihong@cmu.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China</aff><aff id="aff2"><label>b</label>Department of Breast &amp; Thyroid Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</aff><aff id="aff3"><label>c</label>General Surgery Ward 1, Benxi Central Hospital of China Medical University, Benxi, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang 110001, China. Tel.: +86 24 83282191. E-mail: <email>wangzhihong@cmu.edu.cn</email> (Z. Wang); E-mail: <email>haozhang@cmu.edu.cn</email> (H. Zhang).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6343</fpage><lpage>6350</lpage><history><date date-type="received"><day>11</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6343.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6343.pdf"/><abstract><sec><title>Background:</title><p>The 2015 American Thyroid Association guidelines recommend total thyroidectomy (TT) followed by radioactive iodine (RAI) therapy as the primary treatment modality for intermediate-risk papillary thyroid carcinoma (PTC) patients with lateral lymph node metastasis (LLNM). However, the supporting evidence remains insufficient. The clinical superiority of TT versus lobectomy (LT) in this patient population remains unclear, and the optimal surgical approach for intermediate-risk PTC with LLNM continues to be debated.</p></sec><sec><title>Aim:</title><p>This meta-analysis examined the clinical superiority of TT versus LT for intermediate-risk PTC with unilateral LLNM.</p></sec><sec><title>Methods:</title><p>This PRISMA/AMSTAR-compliant meta-analysis (PROSPERO: CRD42023410775) evaluated recurrence-free survival (RFS) in intermediate-risk PTC with unilateral LLNM. Systematic searches of PubMed, Web of Science, and Cochrane Library (2004&#8211;2024) combined Medical Subject Heading terms and title/abstract: (&#8220;papillary thyroid carcinoma&#8221; OR &#8220;papillary thyroid cancer&#8221; OR &#8220;PTC&#8221;) AND (&#8220;lateral cervical lymph node metastasis&#8221; OR &#8220;lateral neck lymph node metastasis&#8221; OR &#8220;lateral lymph node metastasis&#8221; OR &#8220;lateral cervical nodal metastasis&#8221; OR &#8220;N1b&#8221;) AND (&#8220;thyroidectomy&#8221; OR &#8220;total thyroidectomy&#8221; OR &#8220;lobectomy&#8221;). Two investigators independently extracted data on surgical outcomes, adjuvant RAI therapy, and RFS metrics, with quality assessed via Newcastle&#8211;Ottawa Scale. Prespecified subgroup analyses examined RAI utilization and surgical extent impacts. Pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Review Manager 5.3, prioritizing adjusted HR. Heterogeneity was assessed via <italic toggle="yes">I</italic><sup>2</sup> statistics.</p></sec><sec><title>Results:</title><p>Among 609 initially identified references, 8 studies met the inclusion and exclusion criteria, comprising 2462 intermediate-risk PTC patients with unilateral LLNM. Of these, 53.3% (1313/2462) underwent TT, and 46.7% (1149/2462) underwent LT. Compared with the TT group, LT showed no statistically significant difference on RFS (HR&#160;=&#160;1.08, 95% CI 0.83&#8211;1.40, <italic toggle="yes">P</italic> =&#160;0.56). In subgroup analyses: Compared with TT&#160;+&#160;RAI, LT showed no significant difference in RFS (HR&#160;=&#160;0.66, 95% CI 0.40&#8211;1.08, <italic toggle="yes">P</italic> =&#160;0.10); Compared with TT&#160;+&#160;RAI, LT or TT alone showed no significant difference in RFS (HR&#160;=&#160;0.65, 95% CI 0.41&#8211;1.03, <italic toggle="yes">P</italic> =&#160;0.07); Compared with TT alone, LT showed no significant difference in RFS (HR&#160;=&#160;1.16, 95% CI 0.63&#8211;2.12, <italic toggle="yes">P</italic> =&#160;0.64); Compared with TT&#160;+&#160;RAI, TT alone showed no significant difference in RFS (HR&#160;=&#160;0.87, 95% CI 0.42&#8211;1.81, <italic toggle="yes">P</italic> =&#160;0.37).</p></sec><sec><title>Conclusion:</title><p>For intermediate-risk PTC patients with isolated unilateral LLNM, TT, and LT demonstrate comparable oncological outcomes in terms of RFS. Unilateral LLNM alone should not constitute an absolute indication for TT. When no additional high-risk features are present, LT may serve as a preferable alternative to optimize quality of life while maintaining oncological safety.</p></sec></abstract><kwd-group><kwd>lateral lymph node metastasis</kwd><kwd>lobectomy</kwd><kwd>papillary thyroid carcinoma</kwd><kwd>total thyroidectomy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Thyroid carcinoma (TC) is the most prevalent endocrine malignancy, with its incidence rate steadily rising over the past few decades<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>. Differentiated thyroid carcinoma (DTC), which includes papillary thyroid carcinoma (PTC) and follicular TC, accounts for over 90% of TC cases<sup>[<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]</sup>. Although PTC generally demonstrates favorable prognosis, it exhibits significant propensity for cervical lymph node metastasis (LNM). Typically, the metastasis progresses from involvement of the ipsilateral central compartment to lateral neck dissemination and eventually systemic spread<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>. Notably, more than 50% of PTC patients have nodal metastases at the time of initial surgery<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>, and lateral lymph node metastasis (LLNM) is observed in up to 20.9% of cases<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>. Importantly, LLNM is an independent risk factor for postoperative recurrence in PTC patients<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup>.</p><p>Surgical intervention remains the cornerstone of PTC management. However, considerable controversy exists regarding optimal surgical approaches for intermediate-risk PTC with cervical LNM. The 2015 American Thyroid Association guidelines recommend total thyroidectomy (TT) as the initial surgical approach for DTC patients with LLNM, followed by postoperative radioactive iodine (RAI) therapy<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup>. In contrast, the 2018 guidelines from the Japanese Society of Endocrine Surgeons emphasize individualized decision-making. They suggest either TT or lobectomy (LT) based on prognostic factors and patient-specific considerations for intermediate-risk PTC<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>. This shift in paradigm reflects evolving risk stratification strategies. Contemporary guidelines endorsing de-escalated treatment protocols (e.g. reduced TT and RAI utilization) for intermediate-risk patients<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup>.</p><p>The ongoing debate about selecting the surgical approach for intermediate-risk PTC patients with LLNM (N1b disease) arises from several critical considerations. First, while LLNM is recognized as an independent predictor of postoperative recurrence in major staging systems<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup>, the extent of lymph node metastases is included in some of these systems. It seems to increase the risk of mortality only in older patients with clinically significant metastatic lymphadenopathy (clinical N1 disease)<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>. Second, current guidelines lack specific recommendations on RAI administration following TT in LLNM patients. There is persistent controversy over its efficacy in reducing recurrence<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R14" ref-type="bibr">14</xref>]</sup>. Third, existing studies predominantly derive from single-center cohorts with limited sample sizes, potentially compromising their generalizability. Finally, LT demonstrates distinct advantages in preserving contralateral thyroid function, reducing surgical complications, and minimizing postoperative levothyroxine (L-T4) dependency<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>.</p><p>To address these evidence gaps, this systematic review and meta-analysis comprehensively evaluates recurrence-free survival (RFS) outcomes associated with TT versus LT in intermediate-risk PTC patients with LLNM. Our findings aim to guide evidence-based surgical decision-making for this clinically significant patient group.</p></sec><sec sec-type="methods"><title>Materials and methods</title><sec><title>Protocol</title><p>This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews guidelines<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</sup>. The study protocol was prospectively registered in PROSPERO (CRD42023410775). This study followed the TITAN Guidelines 2025 for declarations related to artificial intelligence (AI) research<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>. No AI-generated tools were employed in this study (including but not limited to data analysis, text editing, etc.). All aspects of research design, data interpretation, and manuscript preparation were carried out independently by the authors.</p></sec><sec><title>Inclusion and exclusion criteria</title><p>Intermediate-risk PTC with LLNM (N1b) was defined as clinically (cN1b) or pathologically (pN1b) confirmed nodal involvement with maximum metastatic diameter &lt;3 cm. The inclusion criteria were as follows: (1) retrospective or prospective cohort studies; (2) comparative cohorts receiving TT versus LT with histologically confirmed PTC; (3) unilateral LLNM confirmed by clinical or pathological examination (metastatic node diameter &lt;3 cm); (4) availability of complete data for extraction (e.g. hazard ratios [HRs], survival rates with confidence intervals [CIs]). The exclusion criteria included: (1) non-PTC histology or absence of LLNM; (2) macroscopic extrathyroidal extension or distant metastasis; (3) non-original research (e.g. case reports, reviews, conference abstracts, etc.). The LT group was designated as the intervention group, and the TT was the control group, with RFS serving as the primary endpoint.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>The 2015 American Thyroid Association guidelines recommended that intermediate-risk patients should be considered radioactive iodine therapy after total thyroidectomy (TT), though acknowledging limited evidence strength.</p></list-item><list-item><p>The clinical superiority of TT versus lobectomy (LT) in this patient population remains unclear, and the optimal surgical approach for intermediate-risk papillary thyroid carcinoma (PTC) with lateral lymph node metastasis (LLNM) continues to be debated.</p></list-item><list-item><p>This study represents the first meta-analysis specifically evaluating the clinical impact of surgical approaches (TT vs. LT) on recurrence-free survival in intermediate-risk PTC with LLNM.</p></list-item></list></p></sec></boxed-text></p></sec><sec><title>Search strategy</title><p>A comprehensive literature search was performed across Cochrane Library, PubMed, and Web of Science databases for studies published between January 2004 and December 2024. The search algorithm combined the following Medical Subject Headings terms and title/abstract keywords: (&#8220;papillary thyroid carcinoma&#8221; OR &#8220;papillary thyroid cancer&#8221; OR &#8220;PTC&#8221;) AND (&#8220;lateral cervical lymph node metastasis&#8221; OR &#8220;lateral neck lymph node metastasis&#8221; OR &#8220;lateral lymph node metastasis&#8221; OR &#8220;lateral cervical nodal metastasis&#8221; OR &#8220;N1b&#8221;) AND (&#8220;thyroidectomy&#8221; OR &#8220;total thyroidectomy&#8221; OR &#8220;lobectomy&#8221;).</p></sec><sec><title>Data collection and quality assessment</title><p>After removing duplicates, two independent researchers conducted title/abstract screening followed by a full-text evaluation. Key variables encompassed study design, publication year, country, median follow-up time, surgical outcomes (number of cases and recurrence rates for TT vs. LT), and details of adjuvant therapy (e.g. the proportion of patients receiving RAI therapy). Data extraction was performed using standardized Excel templates, with cross-verification by a third reviewer to resolve discrepancies. We assessed the methodological quality of included studies was appraised using the Newcastle&#8211;Ottawa Scale for cohort studies, with a score of &#8805; 7 stars were considered high quality. The risk of bias assessment followed Cochrane Collaboration recommendations.</p></sec><sec><title>Statistical analysis</title><p>All analyses were performed using Review Manager 5.3. HR with 95% CI was calculated as the effect measure. When available, adjusted HR was prioritized; otherwise, unadjusted HR or estimates derived from Kaplan&#8211;Meier curves were utilized<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup>. The primary analysis compared RFS between TT (or TT&#160;+&#160;RAI) and LT cohorts using pooled HR with 95% CI. Subgroup analyses were conducted to evaluate how surgical extent affected outcomes under specific clinical scenarios. Statistical significance was set at two-tailed <italic toggle="yes">P</italic> &lt;&#160;0.05. Heterogeneity was quantified via I<sup>2</sup>statistics and Cochran&#8217;s <italic toggle="yes">Q</italic> test, with interpretation thresholds: <italic toggle="yes">I</italic><sup>2</sup>&#160;&lt;&#160;25%: low heterogeneity; 25%&#8211;50%: moderate heterogeneity; 51%&#8211;75%: substantial heterogeneity;&#160;&gt;75%: considerable heterogeneity. A fixed-effects model was applied when <italic toggle="yes">I</italic><sup>2</sup>&#160;&lt;&#160;50% and/or <italic toggle="yes">P</italic> &gt;&#160;0.1; otherwise, a random-effects model was employed.</p></sec></sec><sec sec-type="results"><title>Result</title><p>The systematic search initially identified 609 records: PubMed (<italic toggle="yes">n</italic> =&#160;317), Web of Science (<italic toggle="yes">n</italic> =&#160;272), and Cochrane Library (<italic toggle="yes">n</italic> =&#160;20). After removing duplicates and screening title/abstract, 22 articles underwent full-text evaluation. Fourteen studies were excluded based on predefined criteria, ultimately yielding eight eligible studies<sup>[<xref rid="R20" ref-type="bibr">20</xref>&#8211;<xref rid="R27" ref-type="bibr">27</xref>]</sup> for meta-analysis, as detailed in the PRISMA flowchart (Fig. <xref rid="F1" ref-type="fig">1</xref>). This systematic review and meta-analysis included 2462 patients with intermediate-risk PTC and unilateral LLNM. The cohort comprised 53.3% (1313/2462) who received TT and 46.7% (1149/2462) who received LT. Table <xref rid="T1" ref-type="table">1</xref> summarizes the key characteristics of the included studies.<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Flowchart of literature retrieval based on PRISMA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6343-g001.jpg"/></fig>
<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Basic characteristics of the eight included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study (year)</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Years followed</th><th align="center" rowspan="1" colspan="1">Median time (months)</th><th align="center" rowspan="1" colspan="1">Total thyroidectomy/RFS</th><th align="center" rowspan="1" colspan="1">Lobectomy/RFS</th><th align="center" rowspan="1" colspan="1">RAI (%)</th><th align="center" rowspan="1" colspan="1">Quality score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Liu <italic toggle="yes">et al</italic> (2019)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">1996&#8211;2008</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">208 (80.8%)</td><td align="center" rowspan="1" colspan="1">208 (79.1%)</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Song <italic toggle="yes">et al</italic> (2020)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">2010&#8211;2018</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">67 (91.0%)</td><td align="center" rowspan="1" colspan="1">62 (93.5%)</td><td align="center" rowspan="1" colspan="1">35.7</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang <italic toggle="yes">et al</italic> (2020)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">2007&#8211;2016</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">104 (97.1%)</td><td align="center" rowspan="1" colspan="1">160 (97.7%)</td><td align="center" rowspan="1" colspan="1">20.1</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Xu <italic toggle="yes">et al</italic> (2023)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">2000&#8211;2017</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">265 (93.7%)</td><td align="center" rowspan="1" colspan="1">265 (92.3%)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Li <italic toggle="yes">et al</italic> (2024)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">2014&#8211;2021</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">96 (94.8%)</td><td align="center" rowspan="1" colspan="1">102 (94.1%)</td><td align="center" rowspan="1" colspan="1">37.9</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Saito <italic toggle="yes">et al</italic> (2024)</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">2005&#8211;2012</td><td align="center" rowspan="1" colspan="1">156</td><td align="center" rowspan="1" colspan="1">244 (95.4%)</td><td align="center" rowspan="1" colspan="1">157 (93.8%)</td><td align="center" rowspan="1" colspan="1">33.2</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Qiu <italic toggle="yes">et al</italic> (2024)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">2008&#8211;2018</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">76 (94.7%)</td><td align="center" rowspan="1" colspan="1">76 (96.1%)</td><td align="center" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Ji <italic toggle="yes">et al</italic> (2024)</td><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">2011&#8211;2022</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">253 (96.4%)</td><td align="center" rowspan="1" colspan="1">119 (98.3%)</td><td align="center" rowspan="1" colspan="1">59.1</td><td align="center" rowspan="1" colspan="1">7</td></tr></tbody></table></table-wrap>
</p><sec><title>Systematic review of RFS</title><p>Liu <italic toggle="yes">et al</italic><sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> retrospectively analyzed 4230 PTC patients (1996&#8211;2008) and identified 1,087 intermediate-risk cases. Through 1:1 propensity score matching (PSM) based on clinicopathological features, 416 patients with LLNM were included. With a median follow-up of 12.3&#160;years, the 10-year RFS rates were comparable between LT (79.1%) and TT (80.8%) groups (HR&#160;=&#160;1.09, 95% CI 0.74&#8211;1.60, <italic toggle="yes">P</italic> &gt;&#160;0.05). Song <italic toggle="yes">et al</italic><sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> evaluated 2373 papillary thyroid microcarcinoma (PTMC) patients (2010&#8211;2018) and ultimately included 129 unilateral PTMC cases with LLNM. Patients were stratified into LT (<italic toggle="yes">n</italic> =&#160;62) versus TT (<italic toggle="yes">n</italic> =&#160;67) cohorts, with 68.7% of TT patients receiving adjuvant RAI. Structural recurrence occurred in four LT and six TT patients, with no significant difference in RFS (91.89% vs. 88.77%, HR&#160;=&#160;0.72, 95% CI 0.21&#8211;2.43, <italic toggle="yes">P</italic> &gt;&#160;0.05). Wang <italic toggle="yes">et al</italic><sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> analyzed 264 unilateral T1-T2 PTC patients with LLNM (2007&#8211;2016). The cohort comprised 104 TT (39.4%) and 160 LT (60.6%) patients, with a median follow-up of 50 months. Seven recurrences (2.65%) were documented (three in the TT group and four in the LT group), resulting in comparable 5-year RFS rates (96.1% vs. 97.7%, adjusted HR&#160;=&#160;0.79, 95% CI 0.18&#8211;3.56, <italic toggle="yes">P</italic> &gt;&#160;0.05). Xu <italic toggle="yes">et al</italic><sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> conducted a 1:1 PSM analysis of 265 matched pairs from 2000 to 2017. Structural recurrence rates were 6.4% for TT and 7.9% for LT, with no significant 5-year RFS difference (HR&#160;=&#160;1.10, 95% CI 0.58&#8211;2.11, <italic toggle="yes">P</italic> &gt;&#160;0.05). Li <italic toggle="yes">et al</italic><sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> compared 102 LT and 96 TT patients (2014&#8211;2021). Kaplan&#8211;Meier analysis revealed comparable RFS rates between groups (HR&#160;=&#160;1.13, 95% CI 0.36&#8211;3.60, <italic toggle="yes">P</italic> =&#160;0.80), supporting LT as a viable initial treatment strategy for selected patients. Satio <italic toggle="yes">et al</italic><sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> retrospectively analyzed 401 PTC patients (2005&#8211;2012) meeting strict inclusion criteria. Surgical interventions included LT with ipsilateral lymph node dissection (LND) (<italic toggle="yes">n</italic> =&#160;157) versus TT with LND (<italic toggle="yes">n</italic> =&#160;244). With a median follow-up of 13.0&#160;years (IQR 11.2&#8211;15.0), the adjusted 5-/10-/15-year RFS rates were 93.8%/88.4%/84.1% for LT versus 95.4%/92.9%/87.8% for TT (<italic toggle="yes">P</italic> &gt;&#160;0.05), demonstrating equivalent oncological outcomes in intermediate-risk N1b PTC patients. Qiu <italic toggle="yes">et al</italic><sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> performed 1:1 PSM on 76 N1b PTC patient pairs (2008&#8211;2018). While recurrence rates showed no surgical dependence (<italic toggle="yes">P</italic> =&#160;0.70), the LT group exhibited significant advantages in postoperative quality-of-life metrics. These findings suggest preserved thyroid function may optimize clinical outcomes in specific patient subgroups. Ji <italic toggle="yes">et al</italic><sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> evaluated 372 T1-T2 PTC patients (2011&#8211;2022), with 119 undergoing LT and 253 undergoing TT. During follow-up, 11 structural recurrences were documented, with no inter-group difference in RFS (<italic toggle="yes">P</italic> &gt;&#160;0.05). The authors concluded that LT does not compromise prognosis in T1-T2 PTC with unilateral LLNM.</p></sec><sec><title>Meta-analysis of RFS</title><p>This systematic review and meta-analysis included 2462 patients with intermediate-risk PTC and unilateral LLNM. The cohort comprised 53.3% (1313/2462) TT recipients and 46.7% (1149/2462) LT recipients. Pooled analysis demonstrated comparable RFS between LT and TT groups (HR&#160;=&#160;1.08, 95% CI 0.83&#8211;1.40, <italic toggle="yes">P</italic> =&#160;0.56), with forest plot visualization in Figure <xref rid="F2" ref-type="fig">2</xref>. In subgroup analyses: Compared with 47.1% (602/1277) TT&#160;+&#160;RAI, 52.9% (675/1277) LT showed no significant difference in RFS (HR&#160;=&#160;0.66, 95% CI 0.40&#8211;1.08, <italic toggle="yes">P</italic> =&#160;0.10) (Fig. <xref rid="F3" ref-type="fig">3</xref>); Compared with 39.8% (602/1514) TT&#160;+&#160;RAI, 60.2% (912/1514) LT or TT alone showed no significant difference in RFS (HR&#160;=&#160;0.65, 95% CI 0.41&#8211;1.03, <italic toggle="yes">P</italic> =&#160;0.07) (Fig. <xref rid="F4" ref-type="fig">4</xref>); Compared with 28.6% (216/754) TT alone, 71.4% (538/754) LT showed no significant difference in RFS (HR&#160;=&#160;1.16, 95% CI 0.63&#8211;2.12, <italic toggle="yes">P</italic> =&#160;0.64) (Fig. <xref rid="F5" ref-type="fig">5</xref>); Compared with 58.8% (261/444) TT&#160;+&#160;RAI, 41.2% (183/444) TT alone showed no significant difference in RFS (HR&#160;=&#160;0.87, 95% CI 0.42&#8211;1.81, <italic toggle="yes">P</italic> =&#160;0.37) (Fig. <xref rid="F6" ref-type="fig">6</xref>).<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Compare the RFS rates of LT to TT or TT&#160;+&#160;RAI. TT, total thyroidectomy; LT, lobectomy; RAI, radioactive iodine; RFS, recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6343-g002.jpg"/></fig>
<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Compare the RFS rates of LT to TT&#160;+&#160;RAI. TT, total thyroidectomy; LT, lobectomy; RAI, radioactive iodine; RFS, recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6343-g003.jpg"/></fig>
<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Compare the RFS rates of LT or TT to TT&#160;+&#160;RAI. TT, total thyroidectomy; LT, lobectomy; RAI, radioactive iodine; RFS, recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6343-g004.jpg"/></fig>
<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Compare the RFS rates of LT to TT alone. TT, total thyroidectomy; LT, lobectomy; RFS, recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6343-g005.jpg"/></fig>
<fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p>Compare the RFS rates of TT alone to TT&#160;+&#160;RAI. TT, total thyroidectomy; RAI, radioactive iodine; RFS, recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6343-g006.jpg"/></fig>
</p></sec><sec><title>Heterogeneity assessment</title><p>The forest plot analyses demonstrated an <italic toggle="yes">I</italic><sup>2</sup> statistic of 0 across all subgroups, indicating no observed heterogeneity between groups and supporting the robustness of the findings.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our systematic review and meta-analysis compared RFS outcomes between LT and TT in intermediate-risk PTC patients with LLNM. The pooled analysis demonstrated comparable RFS between LT and TT (HR&#160;=&#160;1.08, 95% CI 0.83&#8211;1.40, <italic toggle="yes">P</italic> =&#160;0.56). Consistently, no significant associations were observed across all predefined subgroups (<italic toggle="yes">P</italic> &gt;&#160;0.05). All subgroups exhibited negligible heterogeneity (<italic toggle="yes">I</italic><sup>2</sup>&#160;=&#160;0), reinforcing result reliability. Given LT&#8217;s advantages in lower complication rates and reduced postoperative levothyroxine dependency, these findings provide critical evidence for surgical decision-making in unilateral intermediate-risk PTC with LLNM.</p><p>The optimal surgical approach for intermediate-risk PTC remains contentious, with no definitive consensus regarding the superiority of LT versus TT. Proponents of TT advocate its superiority in enabling postoperative RAI therapy for enhanced thyroglobulin (Tg) monitoring and recurrence surveillance<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R28" ref-type="bibr">28</xref>]</sup>. Ruel <italic toggle="yes">et al</italic><sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup>. demonstrated significantly improved overall survival (OS) in intermediate-risk PTC patients who received RAI after TT (HR&#160;=&#160;0.71, 95% CI 0.62&#8211;0.82, <italic toggle="yes">P</italic> &lt;&#160;0.001). Similarly, Suman <italic toggle="yes">et al</italic><sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> reported prolonged OS in TT&#160;+&#160;RAI patients with high-risk features including cN1 status, lymphvascular invasion, and positive margins (HR&#160;=&#160;0.65, 95% CI 0.51&#8211;0.83, <italic toggle="yes">P</italic> &lt;&#160;0.001). Other studies suggest higher recurrence rates in LT patients necessitating more intensive postoperative surveillance, potentially positioning TT as a more effective therapeutic strategy<sup>[<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]</sup>. Nevertheless, substantial controversy persists regarding the comprehensive clinical benefits of RAI therapy following TT in intermediate-risk populations. Tian <italic toggle="yes">et al</italic><sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> observed elevated structural (HR&#160;=&#160;10.572, 95% CI 2.439&#8211;45.843, <italic toggle="yes">P</italic> =&#160;0.002) and biochemical (HR&#160;=&#160;16.568, 95% CI 3.670&#8211;74.803, <italic toggle="yes">P</italic> &lt;&#160;0.001) recurrence rates in intermediate-risk PTC patients who underwent TT without subsequent RAI treatment. Conversely, multiple investigations have shown no statistically significant improvement in RFS with RAI administration versus observation in TT-treated patients with LNM or LLNM<sup>[<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>]</sup>. Notably, Grani <italic toggle="yes">et al</italic><sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> conducted a prospective analysis of 272 low-to-intermediate risk PTC patients undergoing TT and found no significant prognostic differences between immediate postoperative RAI treatment and deferred management. Jin <italic toggle="yes">et al</italic><sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup> further demonstrated comparable 5-year RFS outcomes across different RAI dosage regimens (100 mCi vs. 150 mCi) in a retrospective analysis of 436 N1b PTC patients (94.1% vs. 96.0%, <italic toggle="yes">P</italic> =&#160;0.351). Our current investigation aligns with these findings, revealing no statistically significant difference in RFS between patients receiving RAI therapy post-TT and those undergoing LT or TT alone (HR&#160;=&#160;0.65, 95% CI 0.41&#8211;1.03, <italic toggle="yes">P</italic> =&#160;0.07). Given the ongoing uncertainty regarding the utility of postoperative RAI therapy in intermediate-risk PTC, future long-term, prospective, and multicenter studies are warranted to validate these findings.</p><p>Current academic consensus maintains that LT represents the optimal surgical approach for low-risk PTC, while demonstrating limited therapeutic appropriateness for intermediate- and high-risk cases. Nevertheless, emerging evidence has re-examined the prognostic implications of TT versus LT in intermediate-risk PTC with LNM. Longitudinal follow-up analyses reveal comparable RFS and disease-specific survival between LT and TT cohorts<sup>[<xref rid="R20" ref-type="bibr">20</xref>&#8211;<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R37" ref-type="bibr">37</xref>]</sup>. A PSM analysis by Xu <italic toggle="yes">et al</italic><sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup>, which included patients treated between January 1, 2000, and December 31, 2017, demonstrated non-inferior RFS outcomes in LT recipients compared to TT counterparts (HR&#160;=&#160;1.10, 95% CI 0.58&#8211;2.11, <italic toggle="yes">P</italic> &gt; 0.05). Satio <italic toggle="yes">et al</italic><sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> conducted a retrospective review (2005&#8211;2012) revealing comparable adjusted RFS rates at 5-, 10-, and 15-year intervals: 93.8%, 88.4%, and 84.1% for LT versus 95.4%, 92.9%, and 87.8% for TT (<italic toggle="yes">P</italic> &gt;&#160;0.05). These investigations collectively suggest equivalent oncological outcomes between TT and LT in select intermediate-risk PTC patients with LLNM. Our study corroborates these findings, demonstrating no statistically significant difference in RFS between LT and TT groups among intermediate-risk PTC with LLNM (HR&#160;=&#160;1.08, 95% CI 0.83&#8211;1.40, <italic toggle="yes">P</italic> =&#160;0.56).</p><p>Notably, LT demonstrates distinct clinical advantages over TT in terms of surgical safety and quality-of-life outcomes<sup>[<xref rid="R38" ref-type="bibr">38</xref>&#8211;<xref rid="R40" ref-type="bibr">40</xref>]</sup>. A PSM analysis by Kwon <italic toggle="yes">et al</italic><sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>, involving 2031 PTC patients, revealed significantly higher rates of transient and permanent hypoparathyroidism in TT groups (<italic toggle="yes">P</italic> &lt;&#160;0.001). Furthermore, TT necessitates higher levothyroxine replacement doses, potentially exacerbating cardiovascular and osseous metabolic risks, whereas residual thyroid tissue preservation in LT may better maintain physiological hormone homeostasis<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>. A prospective study by Gerwen <italic toggle="yes">et al</italic><sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup> evaluating 58 PTC patients identified significantly greater medication necessity beliefs and treatment-related concerns in TT recipients compared to LT patients (<italic toggle="yes">P</italic> &lt;&#160;0.01). Additionally, Chen <italic toggle="yes">et al</italic><sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup> documented more pronounced short-term quality-of-life impairments following TT versus LT. To refine risk-benefit assessments in surgical strategy selection and postoperative quality of life, future long-term, prospective, and multicenter studies remain imperative to further validate these outcomes.</p><p>This study represents the first meta-analysis specifically evaluating the clinical impact of surgical approaches (TT vs. LT) on RFS in intermediate-risk PTC with LLNM. Several methodological limitations warrant careful consideration. First, although we implemented rigorous literature search strategies, our model estimations were derived from non-randomized observational studies with limited sample sizes, inherently constrained by the quality and substantial heterogeneity of available data. This heterogeneity likely stems from variations in inclusion criteria, therapeutic protocols, and follow-up durations across studies, which should be accounted for during data interpretation. Second, the restricted availability of primary datasets precluded comprehensive multivariate analyses. Moreover, the confounding effects of postoperative RAI therapy in TT patients may have influenced long-term outcomes. Third, while the spatial distribution patterns of metastatic lymph nodes correlate significantly with primary tumor locations, the structural limitations of included datasets prevented systematic evaluation of nodal spatial characteristics and primary tumor dimensions-a critical avenue for future research. Consequently, large-scale prospective multicenter trials with standardized protocols are imperative to validate these findings, develop predictive treatment models, and advance personalized therapeutic strategies.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In intermediate-risk PTC cohorts with unilateral LLNM, our analysis demonstrates no statistically significant difference in RFS between TT and LT. These findings suggest that unilateral LLNM alone should not constitute an absolute indication for TT. When devoid of additional high-risk features, LT may represent a preferable option for optimizing quality-of-life outcomes. Future research should prioritize well-designed prospective multicenter studies with extended follow-up periods to establish evidence-based clinical pathways.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank all the participants and support personnel who contributed to the study.</p></ack><fn-group><fn fn-type="other"><p>X.L., Z.G., and C.X. are co-first authors of this study.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 15 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent</title><p>Data were obtained from open-access repositories with waived consent requirements.</p></sec><sec><title>Sources of funding</title><p>This study received funding from the Basic Research Projects of Higher Education Institutions of Liaoning Provincial Department of Education, Natural Science General Program (Grant Number JYTMS20230080), LiaoNing Revitalization Talents Program (Grant Number XLYC2412058), the Applied Basic Research Program of Liaoning Province (Grant Number 2022020225-JH2/1013), the Science and Technology Project of Shenyang City (Grant Number 21-173-9-31).</p></sec><sec><title>Author contributions</title><p>Data curation, formal analysis, investigation, methodology, resources, software, supervision, validation, visualization, writing - original draft: X.L., Z.G., and C.X.; data curation, formal analysis, supervision, writing - review &amp; editing: J.X., J.M., T.H., and M.J.; conceptualization, funding acquisition, project administration, supervision, validation, writing - review &amp; editing: H.Z. and Z.W.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>All the authors declare that they have no conflict of interest.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>PROSPERO, CRD42023410775, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.crd.york.ac.uk/PROSPERO/view/CRD42023410775" ext-link-type="uri">https://www.crd.york.ac.uk/PROSPERO/view/CRD42023410775</ext-link>.</p></sec><sec><title>Guarantor</title><p>Zhihong Wang.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The dataset generated during and/or analyzed during the current study is available from the corresponding author on reasonable request.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>DW</given-names></name><name name-style="western"><surname>Lang</surname><given-names>BHH</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>DSA</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>K</given-names></name><name name-style="western"><surname>Haymart</surname><given-names>MR</given-names></name></person-group>. <article-title>Thyroid cancer</article-title>. <source>Lancet</source><year>2023</year>;<volume>401</volume>:<fpage>1531</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">37023783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)00020-X</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>HE</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group>. <article-title>Cancer statistics, 2022</article-title>. <source>CA Cancer J Clin</source><year>2022</year>;<volume>72</volume>:<fpage>7</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">35020204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21708</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Risk factors associated with lymph node metastasis in papillary thyroid cancer: a retrospective analysis based on 2,428 cases</article-title>. <source>Front Oncol</source><year>2024</year>;<volume>14</volume>:<fpage>1473858</fpage>.<pub-id pub-id-type="pmid">39568564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1473858</pub-id><pub-id pub-id-type="pmcid">PMC11576417</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amendola</surname><given-names>S</given-names></name><name name-style="western"><surname>Piticchio</surname><given-names>T</given-names></name><name name-style="western"><surname>Scappaticcio</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Papillary thyroid carcinoma: &#8804; 10 mm does not always mean pN0. A multicentric real-world study</article-title>. <source>Updates Surg</source><year>2024</year>;<volume>76</volume>:<fpage>1055</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">38446376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13304-024-01779-6</pub-id><pub-id pub-id-type="pmcid">PMC11130044</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name></person-group>. <article-title>Nomogram for predicting central lymph node metastasis in T1-T2 papillary thyroid cancer with no lateral lymph node metastasis</article-title>. <source>Front Endocrinol (Lausanne)</source><year>2023</year>;<volume>14</volume>:<fpage>1112506</fpage>.<pub-id pub-id-type="pmid">36817601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1112506</pub-id><pub-id pub-id-type="pmcid">PMC9930606</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>So</surname><given-names>YK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Son</surname><given-names>YI</given-names></name></person-group>. <article-title>Lateral lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis for prevalence, risk factors, and location</article-title>. <source>Int J Surg</source><year>2018</year>;<volume>50</volume>:<fpage>94</fpage>&#8211;<lpage>103</lpage>.<pub-id pub-id-type="pmid">29329789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2017.12.029</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>The prognostic implication of skip metastasis to lateral neck in patients with papillary thyroid cancer</article-title>. <source>Quant Imaging Med Surg</source><year>2024</year>;<volume>14</volume>:<fpage>9477</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">39698650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/qims-23-1737</pub-id><pub-id pub-id-type="pmcid">PMC11651989</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Lateral lymph node metastasis in papillary thyroid microcarcinoma: a study of 5241 follow-up patients</article-title>. <source>Endocrine</source><year>2024</year>;<volume>83</volume>:<fpage>414</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">37596455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-023-03486-5</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haugen</surname><given-names>BR</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>EK</given-names></name><name name-style="western"><surname>Bible</surname><given-names>KC</given-names></name><etal/></person-group>. <article-title>2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer</article-title>. <source>Thyroid</source><year>2016</year>;<volume>26</volume>:<fpage>1</fpage>&#8211;<lpage>133</lpage>.<pub-id pub-id-type="pmid">26462967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2015.0020</pub-id><pub-id pub-id-type="pmcid">PMC4739132</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Onoda</surname><given-names>N</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>T</given-names></name></person-group>. <article-title>The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: core questions and recommendations for treatments of thyroid cancer</article-title>. <source>Endocr J</source><year>2020</year>;<volume>67</volume>:<fpage>669</fpage>&#8211;<lpage>717</lpage>.<pub-id pub-id-type="pmid">32269182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1507/endocrj.EJ20-0025</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabanillas</surname><given-names>ME</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>DG</given-names></name><name name-style="western"><surname>Durante</surname><given-names>C</given-names></name></person-group>. <article-title>Thyroid cancer</article-title>. <source>Lancet</source><year>2016</year>;<volume>388</volume>:<fpage>2783</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">27240885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)30172-6</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Large-volume lateral lymph node metastasis predicts worse prognosis in papillary thyroid carcinoma patients with N1b</article-title>. <source>Front Endocrinol (Lausanne)</source><year>2021</year>;<volume>12</volume>:<fpage>815207</fpage>.<pub-id pub-id-type="pmid">35185788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2021.815207</pub-id><pub-id pub-id-type="pmcid">PMC8847215</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Momesso</surname><given-names>DP</given-names></name><name name-style="western"><surname>Tuttle</surname><given-names>RM</given-names></name></person-group>. <article-title>Update on differentiated thyroid cancer staging</article-title>. <source>Endocrinol Metab Clin North Am</source><year>2014</year>;<volume>43</volume>:<fpage>401</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">24891169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ecl.2014.02.010</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grani</surname><given-names>G</given-names></name><name name-style="western"><surname>Lamartina</surname><given-names>L</given-names></name><name name-style="western"><surname>Alf&#242;</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk</article-title>. <source>J Clin Endocrinol Metab</source><year>2021</year>;<volume>106</volume>:<fpage>e1717</fpage>&#8211;<lpage>e1727</lpage>.<pub-id pub-id-type="pmid">33377969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgaa973</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>M</given-names></name><name name-style="western"><surname>Miyauchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients</article-title>. <source>Eur J Endocrinol</source><year>2015</year>;<volume>173</volume>:<fpage>333</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">26077156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-15-0138</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><etal/></person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source><year>2021</year>;<volume>372</volume>:<fpage>n71</fpage>.<pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>BC</given-names></name><name name-style="western"><surname>Wells</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both</article-title>. <source>BMJ</source><year>2017</year>;<volume>358</volume>:<fpage>j4008</fpage>.<pub-id pub-id-type="pmid">28935701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.j4008</pub-id><pub-id pub-id-type="pmcid">PMC5833365</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of artificial intelligence - the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>. doi:<pub-id pub-id-type="doi">10.70389/PJS.100082</pub-id>.</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tierney</surname><given-names>JF</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></name><name name-style="western"><surname>Ghersi</surname><given-names>D</given-names></name><name name-style="western"><surname>Burdett</surname><given-names>S</given-names></name><name name-style="western"><surname>Sydes</surname><given-names>MR</given-names></name></person-group>. <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source><year>2007</year>;<volume>8</volume>:<fpage>16</fpage>.<pub-id pub-id-type="pmid">17555582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1745-6215-8-16</pub-id><pub-id pub-id-type="pmcid">PMC1920534</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: a single-institution matched-pair analysis</article-title>. <source>Oral Oncol</source><year>2019</year>;<volume>90</volume>:<fpage>17</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">30846171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2019.01.010</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Comparison of lobectomy and total thyroidectomy in unilateral papillary thyroid microcarcinoma patients with ipsilateral lateral lymph node metastasis without gross extrathyroidal extension</article-title>. <source>World J Surg</source><year>2020</year>;<volume>44</volume>:<fpage>2677</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">32328782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00268-020-05514-1</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gui</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Unilateral Tnm T1 and T2 papillary thyroid carcinoma with lateral cervical lymph node metastasis: total thyroidectomy or lobectomy?</article-title><source>Endocr Pract</source><year>2020</year>;<volume>26</volume>:<fpage>1085</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">33471710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4158/EP-2020-0125</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Comparison of lobectomy vs total thyroidectomy for intermediate-risk papillary thyroid carcinoma with lymph node metastasis</article-title>. <source>JAMA Surg</source><year>2023</year>;<volume>158</volume>:<fpage>73</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">36449303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2022.5781</pub-id><pub-id pub-id-type="pmcid">PMC9713681</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Feasibility of lobectomy in selected patients with unilateral N1b papillary thyroid cancer</article-title>. <source>Ann Surg Oncol</source><year>2025</year>;<volume>32</volume>:<fpage>2344</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">39645560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-024-16643-5</pub-id><pub-id pub-id-type="pmcid">PMC11882689</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsuzu</surname><given-names>K</given-names></name><name name-style="western"><surname>Abdelhamid Ahmed</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>Lobectomy vs total thyroidectomy with ipsilateral lateral neck dissection for N1b intermediate-risk papillary thyroid carcinoma</article-title>. <source>JAMA Otolaryngol Head Neck Surg</source><year>2025</year>;<volume>151</volume>:<fpage>105</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">39602155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoto.2024.3860</pub-id><pub-id pub-id-type="pmcid">PMC11826362</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Recurrence and postoperative quality of life after surgical resection of unilateral cT1&#8211;T3N1bM0 papillary thyroid carcinoma</article-title>. <source>Gland Surg</source><year>2024</year>;<volume>13</volume>:<fpage>1740</fpage>.<pub-id pub-id-type="pmid">39544973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/gs-24-178</pub-id><pub-id pub-id-type="pmcid">PMC11558296</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Lv</surname><given-names>B</given-names></name></person-group>. <article-title>Thyroid lobectomy for unilateral TNM T1 and T2 papillary thyroid carcinoma patients with lateral lymph node metastasis</article-title>. <source>Surgery</source><year>2024</year>;<volume>180</volume>:<fpage>109028</fpage>.<pub-id pub-id-type="pmid">39740604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.surg.2024.109028</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamartina</surname><given-names>L</given-names></name><name name-style="western"><surname>Durante</surname><given-names>C</given-names></name><name name-style="western"><surname>Filetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>DS</given-names></name></person-group>. <article-title>Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature</article-title>. <source>J Clin Endocrinol Metab</source><year>2015</year>;<volume>100</volume>:<fpage>1748</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">25679996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2014-3882</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruel</surname><given-names>E</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Dinan</surname><given-names>M</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>JM</given-names></name><name name-style="western"><surname>Roman</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sosa</surname><given-names>JA</given-names></name></person-group>. <article-title>Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer</article-title>. <source>J Clin Endocrinol Metab</source><year>2015</year>;<volume>100</volume>:<fpage>1529</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">25642591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2014-4332</pub-id><pub-id pub-id-type="pmcid">PMC4399282</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suman</surname><given-names>P</given-names></name><name name-style="western"><surname>Razdan</surname><given-names>SN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CHE</given-names></name><etal/></person-group>. <article-title>Thyroid lobectomy for T1b-T2 papillary thyroid cancer with high-risk features</article-title>. <source>J Am Coll Surg</source><year>2020</year>;<volume>230</volume>:<fpage>136</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">31672668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jamcollsurg.2019.09.021</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macedo</surname><given-names>FIB</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>VK</given-names></name></person-group>. <article-title>Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: a meta-analysis</article-title>. <source>Surg Oncol</source><year>2015</year>;<volume>24</volume>:<fpage>117</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">25956302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.suronc.2015.04.005</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JB</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SG</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy</article-title>. <source>Head Neck</source><year>2019</year>;<volume>41</volume>:<fpage>56</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">30536465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.25356</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>T</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name></person-group>. <article-title>Radioactive iodine therapy decreases the recurrence of intermediate-risk PTC with low thyroglobulin levels</article-title>. <source>J Clin Endocrinol Metab</source><year>2023</year>;<volume>108</volume>:<fpage>2033</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">36715264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgad045</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Noh</surname><given-names>HM</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HM</given-names></name><name name-style="western"><surname>Lim</surname><given-names>YC</given-names></name></person-group>. <article-title>Is postoperative adjuvant radioactive iodine ablation therapy always necessary for intermediate-risk papillary thyroid cancer patients with central neck metastasis?</article-title><source>Ann Surg Oncol</source><year>2021</year>;<volume>28</volume>:<fpage>7533</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">34043093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-021-10164-1</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshizawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Mizuta</surname><given-names>M</given-names></name><name name-style="western"><surname>Tamaki</surname><given-names>H</given-names></name></person-group>. <article-title>Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?</article-title><source>Auris Nasus Larynx</source><year>2021</year>;<volume>48</volume>:<fpage>148</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">32718811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anl.2020.07.005</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YM</given-names></name><etal/></person-group>. <article-title>Clinical outcomes of N1b papillary thyroid cancer patients treated with two different doses of radioiodine ablation therapy</article-title>. <source>Endocrinol Metab (Seoul)</source><year>2020</year>;<volume>35</volume>:<fpage>602</fpage>&#8211;<lpage>09</lpage>.<pub-id pub-id-type="pmid">32981302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3803/EnM.2020.741</pub-id><pub-id pub-id-type="pmcid">PMC7520585</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuura</surname><given-names>D</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>A</given-names></name><name name-style="western"><surname>Harris</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Surgical management of low-/intermediate-risk node negative thyroid cancer: a single-institution study using propensity matching analysis to compare thyroid lobectomy and total thyroidectomy</article-title>. <source>Thyroid</source><year>2022</year>;<volume>32</volume>:<fpage>28</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="pmid">34861772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2021.0356</pub-id><pub-id pub-id-type="pmcid">PMC8792497</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>H</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WG</given-names></name><etal/></person-group>. <article-title>A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study</article-title>. <source>Eur J Endocrinol</source><year>2017</year>;<volume>176</volume>:<fpage>371</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">28089996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-16-0845</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombo</surname><given-names>C</given-names></name><name name-style="western"><surname>De Leo</surname><given-names>S</given-names></name><name name-style="western"><surname>Di Stefano</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Total thyroidectomy versus lobectomy for thyroid cancer: single-center data and literature review</article-title>. <source>Ann Surg Oncol</source><year>2021</year>;<volume>28</volume>:<fpage>4334</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">33566240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-020-09481-8</pub-id><pub-id pub-id-type="pmcid">PMC8253713</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gerwen</surname><given-names>M</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>PV</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>N</given-names></name><name name-style="western"><surname>Mols</surname><given-names>F</given-names></name><name name-style="western"><surname>Genden</surname><given-names>E</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>RM</given-names></name></person-group>. <article-title>Patient-reported outcomes following total thyroidectomy and lobectomy in thyroid cancer survivors: an analysis of the PROFILES registry data</article-title>. <source>Support Care Cancer</source><year>2022</year>;<volume>30</volume>:<fpage>687</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">34363111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-021-06355-x</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence</article-title>. <source>JAMA Surg</source><year>2022</year>;<volume>157</volume>:<fpage>200</fpage>&#8211;<lpage>09</lpage>.<pub-id pub-id-type="pmid">34935859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamasurg.2021.6442</pub-id><pub-id pub-id-type="pmcid">PMC8696698</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>